These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 25243375)

  • 1. Impressive response to pegylated liposomal doxorubicin after allogeneic transplantation in a multi-relapsed Hodgkin's lymphoma.
    Pellegrini C; Maglie R; Argnani L; Pileri S; Zinzani PL
    Hematol Oncol; 2016 Mar; 34(1):49-51. PubMed ID: 25243375
    [No Abstract]   [Full Text] [Related]  

  • 2. Survival analysis of patients with Hodgkin lymphoma who failed high dose chemotherapy and autologous stem cell transplant.
    Elshenawy MA; Shahzad Rauf M; Elhassan TAM; Maghfoor I; Akhtar S
    Ann Hematol; 2018 Jul; 97(7):1229-1240. PubMed ID: 29484455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The combination of thalidomide, cyclophosphamide and dexamethasone is potentially useful in highly resistant Hodgkin's lymphoma.
    García-Sanz R; González-López TJ; Vázquez L; Hermida G; Graciani IF; San Miguel JF
    Eur J Haematol; 2010 Mar; 84(3):266-70. PubMed ID: 19912314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial.
    Schmitz N; Pfistner B; Sextro M; Sieber M; Carella AM; Haenel M; Boissevain F; Zschaber R; Müller P; Kirchner H; Lohri A; Decker S; Koch B; Hasenclever D; Goldstone AH; Diehl V; ;
    Lancet; 2002 Jun; 359(9323):2065-71. PubMed ID: 12086759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ESHAP chemotherapy regimen associated to lenalidomide induces complete isotopic remission in Hodgkin's lymphoma relapsing after autologous stem cell transplantation.
    Tempescul A; Ianotto JC; Eveillard JR; Guillerm G; Berthou C
    Ann Hematol; 2011 Aug; 90(8):971-3. PubMed ID: 21057951
    [No Abstract]   [Full Text] [Related]  

  • 6. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
    Schütt P; Passon J; Ebeling P; Welt A; Müller S; Metz K; Moritz T; Seeber S; Nowrousian MR
    Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized trial of chemotherapy with carmustine, etoposide, cytarabine, and melphalan (BEAM) plus peripheral stem cell transplantation (PBSCT) vs single-agent high-dose chemotherapy followed by BEAM plus PBSCT in patients with relapsed Hodgkin's disease (HD-R2).
    Glossmann JP; Josting A; Pfistner B; Paulus U; Engert A;
    Ann Hematol; 2002 Aug; 81(8):424-9. PubMed ID: 12223998
    [No Abstract]   [Full Text] [Related]  

  • 8. BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients.
    Visani G; Malerba L; Stefani PM; Capria S; Galieni P; Gaudio F; Specchia G; Meloni G; Gherlinzoni F; Giardini C; Falcioni S; Cuberli F; Gobbi M; Sarina B; Santoro A; Ferrara F; Rocchi M; Ocio EM; Caballero MD; Isidori A
    Blood; 2011 Sep; 118(12):3419-25. PubMed ID: 21816830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ESHAP as salvage therapy for relapsed or refractory Hodgkin's lymphoma.
    Labrador J; Cabrero-Calvo M; Pérez-López E; Mateos MV; Vázquez L; Caballero MD; García-Sanz R
    Ann Hematol; 2014 Oct; 93(10):1745-53. PubMed ID: 24863692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [High-dose chemotherapy and autologous stem cell transplantation for refractory and relapsing Hodgkin's disease as first-line therapy-- studies at Sheba Medical Center--Tel Hashomer].
    Avigdor A; Hardan I; Shpilberg O; Raanani P; Grotto I; Ben-Bassat I
    Harefuah; 2000 Sep; 139(5-6):174-9, 248, 247. PubMed ID: 11062945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML.
    Harrison CN; Gregory W; Hudson GV; Devereux S; Goldstone AH; Hancock B; Winfield D; MacMillan AK; Hoskin P; Newland AC; Milligan D; Linch DC
    Br J Cancer; 1999 Oct; 81(3):476-83. PubMed ID: 10507773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Salvage chemotherapy with mini-BEAM for relapsed or refractory Hodgkin's disease prior to autologous peripheral blood stem cell transplantation.
    Fernández-Jiménez MC; Canales MA; Ojeda E; de Bustos JG; Aguado MJ; Hernández-Navarro F
    Haematologica; 1999 Nov; 84(11):1007-11. PubMed ID: 10553161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intensive therapy and autotransplantation in Hodgkin's disease.
    Reece DE; Phillips GL
    Stem Cells; 1994 Sep; 12(5):477-93. PubMed ID: 7804123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment outcome in children and adolescents with relapsed Hodgkin lymphoma--results of the UK HD3 relapse treatment strategy.
    Shankar A; Hayward J; Kirkwood A; McCarthy K; Hewitt M; Morland B; Daw S
    Br J Haematol; 2014 May; 165(4):534-44. PubMed ID: 24754633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BEAM allogeneic transplantation for patients with Hodgkin's disease who relapse after autologous transplantation is safe and effective.
    Cooney JP; Stiff PJ; Toor AA; Parthasarathy M
    Biol Blood Marrow Transplant; 2003 Mar; 9(3):177-82. PubMed ID: 12652468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of relapsed non-Hodgkin's lymphoma after BEAM chemotherapy and autologous transplantation by BU/CY chemotherapy and salvage transplantation.
    Fetscher S; Lübbert M; Kanz L; Behringer D; Finke J; Mertelsmann R; Lange W
    Bone Marrow Transplant; 1997 Mar; 19(5):527-8. PubMed ID: 9052926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 Trial.
    Fermé C; Mounier N; Diviné M; Brice P; Stamatoullas A; Reman O; Voillat L; Jaubert J; Lederlin P; Colin P; Berger F; Salles G
    J Clin Oncol; 2002 Jan; 20(2):467-75. PubMed ID: 11786576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bendamustine efficacy in Hodgkin lymphoma patients relapsed/refractory to brentuximab vedotin.
    Zinzani PL; Derenzini E; Pellegrini C; Celli M; Broccoli A; Argnani L
    Br J Haematol; 2013 Dec; 163(5):681-3. PubMed ID: 24032977
    [No Abstract]   [Full Text] [Related]  

  • 19. High-dose therapy and autologous stem cell transplantation for Hodgkin's lymphoma in relapse or failure after initial chemotherapy : results of the Centre National de Greffe de Moelle Osseuse de Tunis.
    Torjman L; Ladeb S; Lakhal A; Ben Othman T; Abdelkefi A; Ben Abdeladhim A
    Tunis Med; 2007 Jan; 85(1):35-8. PubMed ID: 17424707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mini-BEAM is effective as a bridge to transplantation in patients with refractory or relapsed Hodgkin lymphoma who have failed to respond to previous lines of salvage chemotherapy but not in patients with salvage-refractory DLBCL.
    Moore S; Kayani I; Peggs K; Qian W; Lowry L; Thomson K; Linch DC; Ardeshna K
    Br J Haematol; 2012 Jun; 157(5):543-52. PubMed ID: 22429186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.